{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:52:22Z","timestamp":1789674742379,"version":"4.0.1"},"reference-count":45,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To report on experience using the anti-interleukin 6 receptor antibody tocilizumab (TCZ) to treat severe and therapy-refractory uveitis associated with juvenile idiopathic arthritis (JIA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Retrospective data were gathered from patients with JIA receiving TCZ treatment for uveitis. JIA and related uveitis data (disease onset, activity, structural complications, and topical and systemic antiinflammatory treatment) were evaluated at the start of TCZ (baseline) and every 3 months during TCZ therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>A total of 17 patients (14 women) with active uveitis were included (mean age 15.3 \u00b1 6.9 yrs, mean followup time 8.5 mos). In all patients, uveitis had been refractory to previous topical and systemic corticosteroids, methotrexate (MTX), and other synthetic and biological disease-modifying antirheumatic drugs, including \u2265 1 tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitor. Uveitis inactivity was achieved in 10 patients after a mean of 5.7 months of TCZ treatment (in 3 of them, it recurred during followup) and persisted in the remaining 7 patients. By using TCZ, systemic corticosteroids or immunosuppressives could be spared in 7 patients. Macular edema was present in 5 patients at baseline and improved in all of them under TCZ treatment. Arthritis was active in 11 patients at the initial and in 6 at the final followup visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>TCZ appears to represent a therapeutic option for severe JIA-associated uveitis that has been refractory to MTX and TNF-\u03b1 inhibitors in selected patients. The present data indicate that inflammatory macular edema responds well to TCZ in patients with JIA-associated uveitis.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160231","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T22:04:02Z","timestamp":1473977042000},"page":"2183-2188","source":"Crossref","is-referenced-by-count":113,"title":["Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"43","author":[{"given":"Christoph","family":"Tappeiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mesquida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Carreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Mackensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisu","family":"Kotaniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Bou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Garc\u00eda","family":"de Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Heiligenhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"2018112909362993000_43.12.2183.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00773-4"},{"key":"2018112909362993000_43.12.2183.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-005-0087-3"},{"key":"2018112909362993000_43.12.2183.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem053"},{"key":"2018112909362993000_43.12.2183.4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/acr.22649","article-title":"Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database","volume":"68","author":"Tappeiner","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2018112909362993000_43.12.2183.5","first-page":"936","article-title":"Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis: data from a cross-sectional analysis of a prospective nationwide study","volume":"33","author":"Tappeiner","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909362993000_43.12.2183.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.01.033"},{"key":"2018112909362993000_43.12.2183.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.10.003"},{"key":"2018112909362993000_43.12.2183.8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00296-011-2126-1","article-title":"Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Heiligenhaus","year":"2012","journal-title":"Rheumatology Int"},{"key":"2018112909362993000_43.12.2183.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1485-8"},{"key":"2018112909362993000_43.12.2183.10","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909362993000_43.12.2183.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120583"},{"key":"2018112909362993000_43.12.2183.12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22214"},{"key":"2018112909362993000_43.12.2183.13","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283295fec"},{"key":"2018112909362993000_43.12.2183.14","doi-asserted-by":"publisher","DOI":"10.1038\/nature04753"},{"key":"2018112909362993000_43.12.2183.15","first-page":"493","article-title":"Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis","volume":"10","author":"De Benedetti","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909362993000_43.12.2183.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken489"},{"key":"2018112909362993000_43.12.2183.17","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0338"},{"key":"2018112909362993000_43.12.2183.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(02)00027-8"},{"issue":"Suppl 84","key":"2018112909362993000_43.12.2183.19","first-page":"S75","article-title":"Tocilizumab in severe and refractory non-infectious uveitis","volume":"32","author":"Papo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 84","key":"2018112909362993000_43.12.2183.20","first-page":"S54","article-title":"Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909362993000_43.12.2183.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.02.017"},{"key":"2018112909362993000_43.12.2183.22","first-page":"w13156","article-title":"Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series","volume":"141","author":"Seitz","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"2018112909362993000_43.12.2183.23","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12295"},{"key":"2018112909362993000_43.12.2183.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"2018112909362993000_43.12.2183.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"2018112909362993000_43.12.2183.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120010"},{"key":"2018112909362993000_43.12.2183.27","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","article-title":"Tocilizumab treatment for refractory uveitis-related cystoid macular edema","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2018112909362993000_43.12.2183.28","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","article-title":"Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema","volume":"121","author":"Mesquida","year":"2014","journal-title":"Ophthalmology"},{"key":"2018112909362993000_43.12.2183.29","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21674"},{"key":"2018112909362993000_43.12.2183.30","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909362993000_43.12.2183.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2018112909362993000_43.12.2183.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel030"},{"key":"2018112909362993000_43.12.2183.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.1.38"},{"key":"2018112909362993000_43.12.2183.34","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-011-0481-0"},{"key":"2018112909362993000_43.12.2183.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"2018112909362993000_43.12.2183.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"2018112909362993000_43.12.2183.37","doi-asserted-by":"publisher","DOI":"10.1080\/092739490500200"},{"key":"2018112909362993000_43.12.2183.38","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0444"},{"key":"2018112909362993000_43.12.2183.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2010.04.009"},{"key":"2018112909362993000_43.12.2183.40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"2018112909362993000_43.12.2183.41","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-011-0497-5"},{"key":"2018112909362993000_43.12.2183.42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/s10165-012-0691-0","article-title":"Successful treatment with tocilizumab in a case of Cogan\u2019s syndrome complicated with aortitis","volume":"23","author":"Shibuya","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2018112909362993000_43.12.2183.43","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s00417-012-2243-x","article-title":"Tocilizumab treatment for recalcitrant uveitic macular edema","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2018112909362993000_43.12.2183.44","first-page":"1","article-title":"Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment","volume":"5","author":"Deuter","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"2018112909362993000_43.12.2183.45","doi-asserted-by":"publisher","DOI":"10.1002\/art.11143"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:12:12Z","timestamp":1543500732000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,1]]},"published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.3899\/jrheum.160231"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160231","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]}}}